At the forefront is the development of a fibroblast activation protein (FAP)-targeting compound designed for the detection and treatment of glioblastoma, an aggressive and often fatal brain cancer. Researchers demonstrated that this compound can effectively pinpoint tumors in preclinical models and significantly improve survival outcomes when used in combination with chemotherapy. Their comparative analyses of different radioactive isotopes provided critical insights into how each variant modulates the tumor microenvironment and therapeutic efficacy. This dual-detection and treatment capability showcases a new horizon for theranostics—offering hope against cancers notorious for poor prognosis and treatment resistance.

Advances in imaging precision were achieved through the creation of an ultrahigh-resolution positron emission tomography (PET) scanner capable of depicting molecular activity within the mouse brain with unprecedented detail. By applying a tracer selective for the metabotropic glutamate receptor subtype 1, researchers obtained images that closely matched the gold standard autoradiography. This breakthrough not only bridges the gap between experimental models and human neurological conditions but also empowers scientists to study complex brain diseases with enhanced accuracy, potentially leading to novel therapeutic targets and interventions.

In prostate cancer research, a new one-stop imaging protocol harnesses the combined power of PET, MRI, and CT modalities after a single injection of a prostate-targeted tracer. Evaluated in over a hundred men with suspected cancer recurrence post-prostatectomy, this integrated approach outperformed conventional imaging techniques by detecting a greater number of local recurrences. The streamlined process not only improves diagnostic yield but also promises to reduce patient burden and healthcare costs by consolidating multiple scans into a single session—ushering in a more efficient and patient-centric diagnostic workflow.

Researchers have also explored innovative PET/MRI imaging techniques to enhance the detection of endometriosis, a debilitating condition linked to chronic pelvic pain and infertility in women. Utilizing a FAP-targeted radiotracer, the combined PET/MRI method identified more suspicious lesions compared to MRI alone. Additionally, the imaging results demonstrated a high concordance with surgical findings, suggesting that such advanced molecular imaging could become a valuable tool in the preoperative evaluation of this enigmatic disease. This could dramatically improve patient outcomes by enabling tailored treatment strategies before invasive procedures.

A novel alpha-emitting radiopharmaceutical has emerged as a promising targeted radiotherapy for advanced gastroenteropancreatic neuroendocrine tumors, particularly after the failure of prior treatments. Through specialized imaging techniques, researchers tracked both the parent compound and its radioactive daughter products, revealing detailed patterns of accumulation in tumor tissues and healthy organs. These findings are critical for optimizing radiation delivery and minimizing off-target effects, paving the way for a refined therapeutic agent that exploits the unique biological behaviors of neuroendocrine malignancies.

In another study focused on recurrent prostate cancer, the addition of delayed pelvic PET imaging to the standard PSMA PET/CT protocol has been shown to enhance detection rates. Among more than 200 patients with rising prostate-specific antigen (PSA) levels, the delayed scan uncovered additional suspicious lesions and improved diagnostic confidence. This adjustment may allow clinicians to identify elusive cancer recurrences more effectively, facilitating timely and precise intervention that could ultimately enhance patient survival.

The pursuit of effective treatments against pancreatic ductal adenocarcinoma, one of the deadliest and most aggressive cancers, has driven research into a novel CD44v6-targeting radiopharmaceutical. Preclinical studies in mouse models revealed that this agent accumulates robustly in tumors, slowing their growth and demonstrating enhanced efficacy when combined with chemotherapy. This approach exemplifies the power of molecularly targeted radiotherapy to deliver lethal radiation doses directly to cancer cells while sparing healthy tissue, potentially transforming therapeutic regimens for pancreatic cancer patients.

Turning to the interface of technology and medicine, researchers evaluated public and physician perceptions of artificial intelligence (AI) in clinical decision-making. Utilizing randomized clinical vignettes, the study revealed that adherence to AI recommendations concordant with established medical standards earned more favorable judgments. Intriguingly, when AI advice diverged from standard care, whether physicians accepted or rejected it, evaluations remained similar. These results offer a nuanced understanding of trust dynamics in AI-assisted medicine and could inform the ethical integration of AI tools in healthcare systems worldwide.

Innovative imaging hardware also made headlines with the debut of a next-generation PET scanner designed for enhanced resolution and flexibility applicable to both brain and breast imaging. Initial human trials demonstrated that this system generates sharp, high-contrast images which vividly distinguish intricate brain structures and reveal disease-specific neurological patterns. Additionally, in breast cancer assessments, it delivers detailed visualization of tumor boundaries and heterogeneity—key factors in planning personalized surgical and therapeutic interventions. This technological leap holds promise for elevating diagnostic precision across multiple clinical domains.

A comprehensive review of decades of radiation dose data compared the predictiveness of animal models for human exposure in PET imaging. Findings indicate that short-lived radiotracers yield consistent radiation dose estimates between preclinical and clinical settings. Conversely, longer-lived compounds exhibit greater variability, underscoring the need for careful interpretation of animal data when extrapolating to humans. This insight is vital for regulatory agencies and researchers aiming to balance patient safety with the rapid development of novel imaging agents.

Collectively, these groundbreaking studies herald a new era in nuclear medicine where precision imaging and targeted radiotherapy converge to deliver individualized, effective, and safer medical care. The integration of advanced molecular tracers, cutting-edge scanners, and AI-guided decision-making reflects a paradigm shift toward truly personalized diagnostic and therapeutic approaches. As these technologies progress from laboratory to clinic, they promise to redefine standards of care and improve outcomes for patients facing some of the most formidable medical challenges today.

For professionals and enthusiasts eager to dive deeper into these innovations, the Journal of Nuclear Medicine offers extensive access to the full texts and supplementary materials through its official website. Following the journal on Twitter, Facebook, and LinkedIn ensures timely updates on emerging research and technological breakthroughs that continue to shape the future of molecular imaging and theranostics.

Subject of Research: Precision radiotherapy, molecular imaging, PET imaging, targeted cancer therapies, artificial intelligence in medicine
Article Title: Multiple advanced studies published in The Journal of Nuclear Medicine ahead-of-print in June 2026
News Publication Date: June 5, 2026
Web References: https://jnm.snmjournals.org/
Keywords: Molecular imaging, positron emission tomography, personalized medicine, targeted radiotherapy, glioblastoma, prostate cancer, neuroendocrine tumors, endometriosis, pancreatic cancer, artificial intelligence, PET/MRI imaging, radiopharmaceuticals

The Henry N. Wagner, Jr. Lectureship is awarded annually to an eminent leader whose pioneering contributions have greatly influenced nuclear medicine and molecular imaging. Wagner was a towering figure whose prolific 50-year career included training over 500 professionals and driving advancements in research and clinical practice. His legacy as president of the Society of Nuclear Medicine from 1970 to 1971 continues to inspire innovation and educational progress within the field. Dilsizian’s selection to deliver this lectureship underscores his profound impact and stature within the nuclear medicine community.

Complementing this honor, Dilsizian received the Minoshima-Pappas Transformational Leadership Award, which recognizes visionaries whose leadership has fundamentally reshaped nuclear medicine and molecular imaging, influencing patient care at its core. Named after Dr. Satoshi Minoshima, a past president of SNMMI, and Virginia Pappas, SNMMI’s current CEO, the award celebrates transformative figures whose innovative ideas have led to lasting benefits across the discipline. By receiving this accolade alongside the Wagner Lectureship, Dilsizian exemplifies the synergy of scientific excellence and leadership that drives the future of nuclear medicine.

Dilsizian’s scientific contributions are both numerous and far-reaching. His early research on thallium reinjection revolutionized thallium stress imaging, a technique pivotal in cardiac diagnostics. By refining this method, he enabled more precise detection of myocardial ischemia, thereby improving diagnostic accuracy and subsequent patient management strategies. His investigations into myocardial ischemia as a cause for cardiac arrest and syncope, particularly among young hypertrophic cardiomyopathy patients, led to a paradigm shift in clinical interventions, improving survival and quality of life in this vulnerable population.

At the University of Maryland, Dilsizian and his research collaborators pioneered the application of 18F-fluorodeoxyglucose (FDG) PET/CT imaging for detecting infection in left ventricular assist devices (LVADs). This innovation helped establish a non-invasive, frontline diagnostic approach for a condition traditionally difficult to identify, influencing treatment decisions and patient outcomes. The integration of FDG PET/CT into clinical practice for infection elucidation marked a significant stride toward personalized molecular imaging strategies in cardiac care.

Beyond scientific research, Dr. Dilsizian has been instrumental in elevating the quality standards of nuclear cardiology practice. He has extensively contributed to clinical guidelines and credentialing protocols that ensure uniform competence and high-quality care delivery across institutions. His input into professional training materials and textbooks has augmented educational resources, empowering a new generation of nuclear medicine specialists. Concurrently, his advocacy efforts have catalyzed regulatory reforms and legislative advances that fortify the integration of cutting-edge nuclear imaging methods into routine clinical workflows.

A committed steward of the SNMMI community for over 30 years, Dilsizian’s leadership roles have been diverse and impactful. Serving as SNMMI president from 2019 to 2020, he steered the society through the COVID-19 pandemic, organizing the first fully virtual Annual Meeting and enabling uninterrupted knowledge exchange amid unprecedented challenges. His tenure also included pivotal roles in the Cardiovascular Council, Membership Committee, and Awards Committee, along with participation in the Board of Directors and House of Delegates. His longstanding role as a reviewer for The Journal of Nuclear Medicine for more than two decades further evidences his dedication to advancing scholarly excellence.

Dr. Dilsizian’s influence extends well beyond SNMMI. He has collaborated with major government and professional bodies including the National Institutes of Health (NIH), Nuclear Regulatory Commission, American Heart Association, American College of Cardiology, and the American Society of Nuclear Cardiology (ASNC). His editorial stewardship as deputy editor of JACC Cardiovascular Imaging and board memberships for other scientific journals underscores his commitment to scientific rigor and dissemination of critical knowledge in cardiovascular nuclear medicine.

Throughout his illustrious career, Dr. Dilsizian has garnered a plethora of awards recognizing his scientific, educational, and leadership accomplishments. Highlights include the SNMMI Hermann Blumgart Pioneer Award (2014), designation as a “Master” of ASNC (2016), the Lifetime Achievement Award from the World Federation of Cardiac Imaging and Clinical Cardiology (2019), and the Mario Verani Memorial Lecture Award from ASNC (2024). His prolific scholarly output, consisting of over 280 peer-reviewed manuscripts, eleven books, and 51 book chapters, has substantially enriched the knowledge base of nuclear cardiology and molecular imaging.

Educationally, Dilsizian’s background is exemplary and varied, comprising a medical degree from Tufts University School of Medicine (1982), followed by an internal medicine residency at Georgetown University (1985). His rigorous cardiology fellowships at Boston University Medical Center and Massachusetts General Hospital and a nuclear medicine residency at NIH culminated in a leadership role as director of nuclear cardiology at NIH until 2001. Subsequently, his move to the University of Maryland expanded his impact as division chief of nuclear medicine, advancing both clinical practice and research domains.

The significance of Dr. Dilsizian’s awards was underscored by notable figures within SNMMI. Satoshi Minoshima, MD, PhD, lauded him as a role model for physician-scientists, highlighting his seminal scientific contributions to cardiovascular diagnostics and treatment paradigms. Virginia Pappas, CAE, reiterated his deservingness, noting that his leadership and innovation have driven meaningful, patient-centered advances in nuclear cardiology worldwide. Their commendations reflect the broad respect and admiration Dr. Dilsizian commands across diverse facets of the nuclear medicine landscape.

In the evolving era of precision medicine, Dr. Dilsizian’s work embodies the integration of molecular imaging technologies with patient-specific diagnostic and therapeutic approaches. His pioneering efforts have not only enhanced our capacity to diagnose and monitor cardiovascular diseases with unprecedented accuracy but also accelerated the adoption of theranostic strategies that tailor interventions to molecular signatures. This transformational leadership continues to inspire the nuclear medicine community as it navigates the promising frontiers of personalized cardiovascular care.

As nuclear medicine and molecular imaging continue to redefine the diagnostic landscape, leaders like Dr. Vasken Dilsizian exemplify the fusion of rigorous scientific inquiry with visionary governance. His honors at the SNMMI 2026 Annual Meeting serve as a testament to his lifelong dedication to research excellence, clinical innovation, and societal impact. The field eagerly anticipates further advancements fueled by his scientific insight and leadership as molecular imaging cements its role in delivering precise, transformative patient care.

Subject of Research: Nuclear Medicine, Molecular Imaging, Nuclear Cardiology, Cardiovascular Diagnostics

Article Title: Vasken Dilsizian, MD, Honored with Wagner Lectureship and Transformational Leadership Award at SNMMI 2026 Annual Meeting

News Publication Date: May 30, 2026

Web References:

• Society of Nuclear Medicine and Molecular Imaging (SNMMI): snmmi.org

Image Credits: Courtesy of SNMMI

Keywords: Molecular imaging, Nuclear medicine, Nuclear cardiology, Positron emission tomography, Personalized medicine, FDG PET/CT, Thallium imaging, Myocardial ischemia, Cardiovascular diagnostics, Transformational leadership, Clinical innovation, Precision medicine

Nuclear medicine employs radiopharmaceuticals that emit gamma rays or positrons, allowing clinicians to image physiological processes at the molecular level. These sophisticated imaging techniques enable earlier and more accurate disease detection than traditional anatomical imaging modalities. The clinical applications showcased will highlight innovations such as improved sensitivity and specificity in tumor localization, cardiac perfusion imaging, and neurotransmitter metabolism assessments. These capabilities provide invaluable insights into disease mechanisms, facilitating personalized treatment planning and more effective management strategies.

The SNMMI 2026 Annual Meeting will convene over 8,000 professionals worldwide, encompassing physicians, researchers, technologists, and industry leaders dedicated to advancing nuclear medicine. The program is extensive and robust, featuring over 150 scientific presentations and continuing education sessions designed to disseminate state-of-the-art knowledge. These sessions will cover cutting-edge developments in oncology, cardiology, and neurosciences, presenting novel radiotracers, imaging hardware improvements, and integration of artificial intelligence for image analysis.

Oncology remains at the forefront, with new radiopharmaceuticals targeting specific tumor markers to improve the detection and quantification of malignancies. Advances in positron emission tomography (PET) tracers allow visualization of cancer metabolism and receptor expression, thereby enabling clinicians to tailor therapies such as peptide receptor radionuclide therapy (PRRT) with unprecedented precision. Beyond diagnosis, these agents are instrumental in therapy monitoring, providing real-time feedback on treatment efficacy.

Cardiovascular imaging also benefits immensely from nuclear medicine. Techniques to assess myocardial blood flow, viability, and perfusion offer a comprehensive evaluation of ischemic heart disease and heart failure. By refining radiotracer kinetics and image reconstruction algorithms, researchers are improving diagnostic accuracy while reducing radiation exposure. These advancements are vital for stratifying patients’ risk and guiding interventions that enhance clinical outcomes.

Neurological applications of molecular imaging have seen remarkable progress. Radiotracers designed to bind amyloid plaques and tau proteins are instrumental in the early detection and differentiation of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Functional imaging of neurotransmitters and cerebral blood flow sheds light on pathophysiological processes, paving the way for innovative therapeutic approaches and patient monitoring.

A key highlight of the 2026 meeting is the emphasis on innovations in imaging equipment and instrumentation. Attendees will be introduced to state-of-the-art PET and single-photon emission computed tomography (SPECT) systems with improved spatial and temporal resolution, enabling more precise quantification of biological processes. Hybrid imaging modalities such as PET/MRI demonstrate how anatomical and molecular data can be integrated seamlessly, enhancing diagnostic confidence and clinical decision-making.

The meeting also underscores the translation of nuclear medicine advances into real-world clinical practice. Case studies and clinical trials will be presented, illustrating how molecular imaging impacts patient management in diverse settings. This translational focus ensures that discoveries lead to tangible benefits, including earlier interventions, personalized therapeutic regimens, and improved monitoring of disease progression or remission.

To facilitate access and participation, the SNMMI 2026 Annual Meeting will adopt a hybrid format. The venue at the Los Angeles Convention Center will welcome attendees in person while simultaneously offering a virtual platform equipped with interactive tools for live education sessions, on-demand content, and networking opportunities. This innovative approach ensures that the global community of nuclear medicine professionals can engage regardless of geographical constraints or scheduling challenges.

The virtual platform will feature an extensive digital exhibit hall where the latest imaging technologies and radiopharmaceutical products will be showcased. This enables participants to stay abreast of technological advances and commercial offerings that are shaping the future of molecular imaging. Additionally, the Science Pavilion will spotlight cutting-edge research, fostering dialogue between academia, industry, and clinical practitioners.

Importantly, the SNMMI Annual Meeting encourages the dissemination of knowledge through media channels. Journalists and media professionals interested in covering the event are invited to register in advance to access all sessions and materials. The presence of a dedicated communications team ensures that nuanced and technically accurate information is available, facilitating comprehensive coverage of this transformative meeting.

As nuclear medicine continues to mature, the SNMMI Annual Meeting exemplifies the dynamic evolution of this discipline. By integrating molecular insights into clinical workflows, nuclear medicine not only enhances diagnostic precision but also propels the era of personalized medicine forward. The 2026 meeting promises to be a pivotal event in heralding new standards of care characterized by earlier diagnosis, customized treatments, and improved patient outcomes through molecular imaging.

—

Subject of Research: Molecular Imaging and Targeted Radiopharmaceutical Therapies in Nuclear Medicine
Article Title: The Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting: Pioneering Advances in Molecular Imaging for Precision Medicine
News Publication Date: Not provided
Web References: https://www.snmmi.org/
Keywords: Molecular imaging, Medical imaging, Positron emission tomography, Personalized medicine, Nuclear medicine, Radiopharmaceutical therapies, Oncology imaging, Cardiology imaging, Neurological imaging, PET/MRI, Radiotracers, Hybrid event

At the forefront of imaging technology, one study delved into the capabilities of continuous bed motion combined with ultrahigh sensitivity in total-body PET/CT scans. This novel approach addresses a critical challenge in nuclear medicine: balancing scan speed and image quality without compromising diagnostic accuracy. Using a combination of phantom models and human patient data, the researchers demonstrated that continuous bed motion allows for more comprehensive whole-body imaging with minimal degradation in recovery coefficients and spatial resolution. This breakthrough not only shortens scan times but also sustains robust correlations in lesion and tissue uptake metrics, paving the way for faster, more reliable clinical workflows in oncologic and inflammatory disease assessment.

Expanding the diagnostic horizon beyond conventional applications, another research team introduced a nanobody-based PET tracer specifically designed to track myeloid cell dynamics during SARS-CoV-2 infection. Utilizing nonhuman primate models, the study revealed an unprecedented ability to visualize immune activation and inflammation in lymphoid organs such as lymph nodes, spleen, and bone marrow—regions often overlooked in traditional pulmonary-focused imaging. This innovative tracer permits real-time monitoring of the complex immune responses underlying COVID-19 progression and recovery, offering novel insight into systemic inflammation and opening avenues for therapeutic intervention and disease staging.

Complementing these technological strides, a novel PET imaging tracer labeled with gallium-68, ⁶⁸Ga-DOTA-MGS5, was evaluated in a pioneering pilot study targeting cholecystokinin 2 (CCK2) receptors. This receptor is overexpressed in medullary thyroid carcinoma (MTC) and certain neuroendocrine tumors (NETs). The results showcased compelling lesion detection capabilities and significant radiotracer uptake in MTC and bronchopulmonary NETs, underscoring its potential as a superior diagnostic tool. However, the tracer’s efficacy appeared limited in gastroenteropancreatic NETs, suggesting that receptor heterogeneity across tumor types necessitates further molecular characterization for optimal clinical utility.

Another highly innovative approach was the development of a CD70-specific radiotracer, ⁴⁴Sc-CHX-A″-DTPA-RCCB6, tested primarily in Burkitt lymphoma models. CD70, a surface antigen of the tumor necrosis factor family, is markedly expressed in diverse malignancies and represents a promising target for imaging and therapy. Preclinical evaluations demonstrated the tracer’s strong selective uptake in CD70-expressing tumors while effectively sparing low-expression tissues, indicating high specificity and potential for enhanced disease staging, treatment monitoring, and perhaps even targeted radionuclide therapy. This breakthrough underscores the transformative potential of receptor-driven precision imaging agents in hematologic oncology.

In the realm of therapeutic innovation, the synergistic combination of PSMA-targeted radiopharmaceutical therapy with immunotherapy in prostate cancer was extensively reviewed. While ¹⁷⁷Lu-PSMA-617 has already revolutionized treatment paradigms by markedly improving survival, resistance and immunosuppressive tumor microenvironments pose substantial hurdles. The review synthesized emerging preclinical and clinical evidence supporting the addition of immune checkpoint inhibitors to PSMA radiotherapy. By potentially overcoming tumor-induced immune evasion, this combined approach promises to amplify antitumor immunity, prolong clinical responses, and set the stage for next-generation multimodal therapies that harness both radiation and immunologic mechanisms for durable cancer control.

Together, these studies exemplify how advances in molecular imaging and theranostics are refining the precision medicine paradigm. By enabling simultaneous diagnostic evaluation and treatment monitoring tailored to individual molecular signatures, these techniques minimize unnecessary interventions, optimize therapeutic efficacy, and improve patient quality of life. With total-body imaging capable of rapid comprehensive scans, immune cell-specific tracers elucidating systemic disease processes, and receptor-targeted agents enhancing tumor delineation, nuclear medicine stands poised to shift from a diagnostic tool to a cornerstone of personalized oncology and infectious disease management.

The integration of ultrahigh sensitivity detectors with continuous bed motion technology heralds a new era where scan durations can be drastically reduced without sacrificing image fidelity. Such efficiency is critically important not only for patient comfort but also for expanding throughput in busy clinical settings—a pivotal consideration as nuclear medicine moves into more routine applications. Moreover, emerging tracers with nanobody scaffolds illustrate the field’s commitment to leveraging biologic specificity, enabling the imaging of cellular populations and molecular pathways previously inaccessible in vivo.

Notably, the applications span diverse clinical entities, from viral infections to neuroendocrine tumors and hematologic malignancies, highlighting the versatility of PET imaging combined with molecular targeting. The ability to visualize lymphoid organ involvement in infectious diseases like COVID-19 opens doors to understanding post-infection sequelae and tailoring immunomodulatory therapies. Similarly, targeting CCK2 and CD70 receptors spotlights the nuanced biology underpinning tumor heterogeneity, providing insights critical for selecting patients likely to benefit from radiotheranostic interventions.

The reviewed evidence for combining PSMA radiotherapy with immune checkpoint blockade represents a critical shift toward multimodal treatment strategies. It underscores the importance of addressing tumor microenvironment-induced resistance mechanisms to sustain and enhance patient responses. As immune-modulating therapies continue to evolve, pairing them with precisely targeted radiopharmaceuticals may well become the new standard of care for aggressive and recurrent prostate cancers, and potentially other malignancies expressing similar surface markers.

This batch of state-of-the-art research collectively signals the burgeoning impact of molecular imaging and theranostics on clinical practice. It reiterates the necessity of continued innovation in tracer development, imaging hardware, and therapeutic combinations to surmount current limitations and unlock the full potential of personalized nuclear medicine. Through initiatives like those published in The Journal of Nuclear Medicine, the scientific community is equipped with critical knowledge propelling the field forward—toward more accurate diagnostics, effective treatments, and ultimately, improved patient outcomes worldwide.

For practitioners, patients, and researchers alike, these advances affirm the transformative promise of precision medicine driven by molecular imaging. As the field evolves, adoption of cutting-edge tracers and the integration of immunotherapy with radiopharmaceuticals are anticipated to become mainstays in oncology and infectious disease care pathways. The collaborative synergy between molecular biology, nuclear physics, and clinical medicine encapsulated in these studies provides a vivid illustration of how interdisciplinary efforts accelerate progress in healthcare innovation.

To explore the full collection of these exciting developments and upcoming research, readers are encouraged to visit The Journal of Nuclear Medicine website and follow the Society of Nuclear Medicine and Molecular Imaging’s social media channels for ongoing updates. This suite of novel tools and approaches embodies the proactive spirit of modern medical science, continuously pushing boundaries to better understand and combat complex diseases through personalized, molecularly informed strategies.

Subject of Research: Nuclear medicine and molecular imaging advances focusing on PET/CT imaging, novel radiotracers, and combination therapies in oncology and infectious disease.

Article Title: Advancements in PET/CT Imaging, Novel Radiotracers, and Combined Radiopharmaceutical-Immunotherapeutic Strategies Published in The Journal of Nuclear Medicine

News Publication Date: August 29, 2025

Web References:

• https://doi.org/10.2967/jnumed.125.270078
• https://doi.org/10.2967/jnumed.125.269721
• https://doi.org/10.2967/jnumed.125.269863
• https://doi.org/10.2967/jnumed.125.269991
• https://doi.org/10.2967/jnumed.125.270317

Keywords: Molecular imaging, Medical imaging, Positron emission tomography, Theranostics, Radiopharmaceutical therapy, Nanobody tracers, Total-body PET/CT, CD70, CCK2 receptor, PSMA, Immune checkpoint inhibitors, SARS-CoV-2 imaging

At the heart of the discussions was the explosion of new technologies and methodologies reshaping nuclear medicine practice. Cutting-edge topics included the application of theranostics—an emerging precision medicine approach combining targeted diagnostic imaging with personalized therapy—to improve outcomes across oncology, cardiology, and neurology. Emerging radiotracers such as FAPI-targeted agents and novel PET probes were spotlighted for their potential to unveil new biological insights and increase the accuracy of disease detection. These innovations promise to deepen clinicians’ abilities to characterize tumor microenvironments, monitor treatment response, and ultimately guide patient-specific therapeutic strategies.

Artificial intelligence (AI) took center stage as a transformative tool in molecular imaging workflows, addressing challenges from image acquisition to data interpretation. The meeting’s AI Showcase: Innovation in Action brought together leading academic researchers and industry pioneers to demonstrate state-of-the-art AI models enhancing image reconstruction, lesion detection, and quantitative analysis. These machine learning techniques expedite processing times and improve diagnostic precision, potentially enabling clinicians to extract more nuanced information from molecular imaging exams. As AI integration into nuclear medicine rapidly matures, its implications for personalized care and clinical trial design were discussed with great enthusiasm.

The Science Pavilion was a focal point of discovery, featuring over 750 research posters that covered breakthroughs from fundamental radiochemistry to clinical applications of novel imaging agents. These posters highlighted efforts to improve radiotracer specificity, reduce radiation exposure, and optimize dosimetry protocols. Sophisticated imaging quantification techniques, including myocardial flow reserve assessments using exercise stress F-18-Flurpiridaz PET, were presented, reflecting advances in noninvasive cardiovascular diagnostics. Such quantitative imaging biomarkers are becoming essential tools not only for diagnosis but also for prognostication and therapeutic monitoring.

Beyond traditional session formats, the 2025 Annual Meeting innovated programming to better reflect the interdisciplinary nature of nuclear medicine. The inaugural “Intersection Sessions” explored the convergence of molecular imaging with other medical specialties and emerging technologies, fostering dialogue on integrated diagnostic approaches. Arena sessions and the Eye on U stage offered dynamic educational experiences, while a revamped Knowledge Bowl engaged attendees in a fast-paced competition testing clinical expertise and scientific knowledge—underscoring the meeting’s dedication to both cutting-edge science and community building.

This year also marked SNMMI’s celebration of global collaboration, with Australia and New Zealand designated as the 2025 Highlight Countries. This international focus showcased the pioneering research and clinical advances emerging from these countries, particularly in theranostics and molecular imaging innovation. Presentations at the Henry N. Wagner, Jr., MD, Lecture by Andrew Scott, MD, illustrated significant progress in theranostic applications internationally, underscoring the increasing interconnectedness of research efforts aimed at precision medicine on a global scale.

Leadership transition at SNMMI was a notable event, installing Dr. Jean-Luc C. Urbain as president. Dr. Urbain’s vision emphasized the critical importance of continuous education to keep pace with rapid scientific evolution. Alongside him, Dr. Heather Jacene assumed the role of president-elect, while Dr. Gary Ulaner became vice president-elect. The Technologist Section also welcomed new leaders, exemplifying SNMMI’s commitment to inclusive, multidisciplinary governance and its recognition of vital contributions from technologists and allied health professionals within the nuclear medicine community.

Recognition of exemplary scientific achievement was a highlight with a series of prestigious awards. Wynn Volkert, PhD, received the Georg Charles de Hevesy Nuclear Pioneer Award, honoring seminal contributions to the field, including innovations in radiopharmaceutical chemistry. Julie Price, PhD, was celebrated with the Paul C. Aebersold Award for her outstanding achievements in basic nuclear medicine science, particularly in tracer development and imaging methodology. The Sam Gambhir, MD, Trailblazer Award was bestowed upon Steven Liang, PhD, for his impactful translational research merging molecular imaging with therapeutic innovation.

The prestigious SNMMI Image of the Year was presented, featuring a comparative analysis of 18F-AlF-NOTA-PCP2 and 18F-FDG uptake in head and neck cancer patients, created by Yong Wang, MD, and colleagues. This imaging work addressed the challenging question of predicting PD-L1 expression using PET/CT, advancing the field’s understanding of immunotherapy biomarkers through innovative radiotracer development. Simultaneously, the Abstract of the Year recognized Robert de Kemp, PhD, for his work quantifying myocardial flow reserve using exercise stress F-18-Flurpiridaz PET imaging, representing a critical step forward in noninvasive cardiovascular imaging.

The Hal Anger Lecture, delivered by Yuni Dewaraja, PhD, explored the future trajectory of dosimetry-driven clinical trials and predictive modeling, emphasizing the role of personalized radiation dose calculations in improving patient safety and therapy efficacy. Novel imaging techniques and computational methodologies highlighted in this lecture promise to refine both diagnostic accuracy and therapeutic planning. The conclusion of the meeting featured the Henry N. Wagner, Jr., Highlights Symposium, where experts synthesized the meeting’s most important scientific advancements, identifying trends that will shape the field in the coming years.

Looking ahead, SNMMI announced its next Annual Meeting will take place in Los Angeles, California, from May 30 to June 2, 2026. Continuing its tradition of fostering innovation and collaboration, the upcoming meeting promises to build upon the momentum generated in New Orleans—maintaining SNMMI’s role as a global leader in advancing nuclear medicine and molecular imaging science. Interested attendees and stakeholders are encouraged to follow developments and register through the official website.

The 2025 SNMMI Annual Meeting illustrated the vibrant and evolving landscape of nuclear medicine, showcasing how technological advancements such as novel radiotracers, artificial intelligence integration, and precision dosimetry are converging to accelerate the path towards individualized cures. By embracing cross-disciplinary collaboration and innovative educational formats, the meeting reaffirmed the critical role of community and knowledge exchange in driving breakthroughs that promise to transform clinical practice worldwide.

Subject of Research: Advances and innovations in nuclear medicine, molecular imaging, and theranostics, with emphasis on new radiotracers, AI integration, personalized dosimetry, and clinical applications.

Article Title: SNMMI 2025 Annual Meeting: Accelerating the Cure Through Innovation in Nuclear Medicine and Molecular Imaging

News Publication Date: June 25, 2025

Web References:

• www.snmmi.org/am
• www.snmmi.org

Image Credits: Image courtesy of SNMMI.

Keywords: Molecular imaging; Medical imaging; Positron emission tomography; Theranostics; Artificial intelligence; Radiotracers; Dosimetry; Nuclear medicine

One of the most compelling advancements involves a newly developed positron emission tomography (PET) radioligand known as ^11C-ZTP-1, which specifically targets phosphodiesterase 4B (PDE4B) — an enzyme intricately connected to neuroinflammation and various neuropsychiatric disorders. The ability of ^11C-ZTP-1 to selectively image PDE4B was rigorously validated in preclinical models including rats and non-human primates. This short-lived radiotracer’s unique properties facilitate the possibility of multiple scans within the same day, an innovation that could accelerate both fundamental brain research and the clinical development pipeline for novel neurotherapeutics by providing dynamic, temporal mapping of enzyme activity in vivo.

Expanding our understanding of breast cancer imaging, another pioneering study challenges the traditional categorization of “false positives” in PET imaging by utilizing ^89Zr-labeled antibodies. This approach has demonstrated the capacity to detect HER2-low breast cancer lesions, a subset formerly misclassified and overlooked due to limitations of earlier imaging modalities. This revelation not only broadens the diagnostic scope of HER2 PET imaging but also introduces the potential for identifying patients who could benefit from emerging HER2-targeted therapies, representing a paradigm shift in oncological precision medicine that prioritizes molecular heterogeneity.

Further enhancements in brain imaging are demonstrated by the introduction of ^18F-K-40, a novel PET tracer that permits visualization of AMPA receptors in living human subjects. AMPA receptors, fundamental to excitatory neurotransmission and synaptic plasticity, play a pivotal role in cognitive processes and neurological health. By matching the specificity and sensitivity of prior tracers with the added advantage of a longer half-life, ^18F-K-40 enables more flexible and accessible imaging protocols, promising to deepen investigations into neurological and psychiatric diseases where AMPA receptor dysfunction is implicated, such as epilepsy, depression, and neurodegeneration.

In a separate investigation, whole-body PET imaging using ^11C-carfentanil, a selective agonist for μ-opioid receptors, has unveiled significant sex-based differences in receptor distribution and naloxone-mediated receptor blockade within the central nervous system. By capturing the nuanced neurobiological variations between men and women in brain regions associated with pain modulation and addiction, this study provides critical insights that could inform sex-specific strategies for managing opioid use disorder and improving the efficacy of analgesic therapies. Understanding these distinctions enhances our grasp of opioid pharmacodynamics and may lead to more personalized approaches in pain medicine and addiction treatment.

Parallel to these empirical studies, a comprehensive review articulates the expanding role of molecular imaging in human phenomics—the systemic study of phenotypes at a complexity scale. Integrating molecular imaging with multiomics datasets and artificial intelligence (AI), this research underscores the transformative potential of such synergy to offer quantitative, predictive insights. This systems-level approach moves beyond traditional diagnostics, fostering preclinical intervention strategies and facilitating a precision health framework centered on individualized biological complexity and continuous monitoring.

The frontiers of personalized cancer imaging and therapy are also pushed forward through investigations targeting the gastrin-releasing peptide receptor (GRPR). Recognized for its overexpression in multiple tumors, GRPR stands as a promising biomarker and therapeutic target. The transition from bench to bedside is explored, emphasizing the dual role of GRPR-based molecular imaging in both diagnosing diverse cancers and delivering targeted radionuclide therapy. This approach embodies the principles of theranostics, thereby optimizing patient selection and therapeutic efficacy while minimizing off-target effects.

Collectively, these studies exemplify a multifaceted advancement of nuclear medicine, leveraging sophisticated tracer chemistry, enhanced imaging techniques, and system biology approaches to drive forward precision medicine. The implications extend from improved brain disorder management and cancer therapeutics to refined diagnostic accuracy, establishing new standards for molecular imaging’s integration into clinical workflows. These innovations hint at a future where individualized treatment selection and comprehensive phenomic assessment are hallmarks of patient care.

Moreover, these pioneering PET imaging tools highlight a key shift toward creating tracers tailored not only for improved diagnostic clarity but also for enabling dynamic therapeutic monitoring. The ability to visualize enzymatic activity, receptor binding, and cellular heterogeneity in vivo opens unparalleled avenues for drug development, patient stratification, and real-time treatment assessment, cultivating an era of truly personalized medicine underpinned by actionable molecular insights.

Advancements in whole-body imaging, such as those achieved with ^11C-carfentanil, demonstrate the feasibility of moving beyond regional brain studies to systems-level interrogation of receptor distributions and pharmacokinetics. This approach facilitates a holistic understanding of complex biological systems and sexes differences, which are often underappreciated in neuropharmacology—offering fertile ground for new discoveries that properly integrate biological diversity into therapeutic design.

The integration of artificial intelligence and multiomics into molecular imaging reveals an exciting interdisciplinary frontier, exploiting the vast data generated through imaging technologies to create predictive models and refined diagnostics. This bidirectional relationship harnesses AI’s capacity to decode complex imaging patterns, while molecular imaging provides the spatially and temporally dense data necessary for nuanced model training—a symbiosis poised to revolutionize predictive medicine, early disease detection, and personalized intervention strategies.

As the field advances, the translational pipeline for molecular imaging agents such as those targeting PDE4B and GRPR is essential for transforming laboratory discoveries into clinical realities. Accelerating regulatory approval, expanding accessibility, and ensuring cost-effectiveness remain challenges, yet the potential impact on patient diagnosis, treatment personalization, and outcome prediction affirms the immense value of these innovations for modern healthcare systems.

The Journal of Nuclear Medicine continues to be at the forefront of disseminating pivotal research that redefines our approach to molecular diagnostics and therapeutics. With a global audience exceeding 15 million annual accesses, the journal serves as an indispensable resource for clinicians, researchers, and industry stakeholders dedicated to harnessing nuclear medicine’s potential to improve patient lives.

For the latest in molecular imaging advancements, practitioners and researchers are encouraged to explore JNM’s comprehensive coverage as the field moves toward increasingly sophisticated, integrative, and patient-specific methodologies that stand to reshape the landscape of healthcare.

Subject of Research: Molecular imaging innovations in neuroscience, oncology, and precision health

Article Title: Various – including “New Brain Imaging Tool Targets Key Enzyme in Mental Health” and “Targeting GRPR: A New Frontier in Personalized Cancer Imaging and Therapy”

News Publication Date: May 9, 2025

Web References:
https://doi.org/10.2967/jnumed.124.269159
https://doi.org/10.2967/jnumed.124.269227
https://doi.org/10.2967/jnumed.124.269405
https://doi.org/10.2967/jnumed.124.269413
https://doi.org/10.2967/jnumed.124.267660
https://doi.org/10.2967/jnumed.124.269444

Keywords: Molecular imaging, PET tracers, PDE4B, HER2-low breast cancer, AMPA receptors, μ-opioid receptors, GRPR, precision medicine, theranostics, neuropsychiatric disorders, molecular phenomics, sex differences, multiomics, artificial intelligence